NSCLC
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
NSCLC
Jul 26, 2024, 15:10 |
Insight
ASCO's rapid guideline update for the management of stage III NSCLC
American Society of Clinical Oncology (ASCO) shared on LinkedIn: "Just issued: Rapid guideline update for…
Jul 26, 2024, 06:54 |
Insight
Discussions around updated OS data from Aegean Trial
Discussions around updated OS data from Aegean Trial Amol Akhade shared a post on X:…
Jul 26, 2024, 06:20 |
Blog
Hossein Borghaei discusses how CTLA4 remains relevant for NSCLC at DC Lung24
Stephen V Liu shared on X: "Dr. Hossein Borghaei from Fox Chase Cancer Center discusses how…
Jul 25, 2024, 23:48 |
Blog
ESTRO - To Escalate or to De-Escalate Radiation Dose in Stage 3 NSCLC?
European Society for Radiotherapy and Oncology shared on LinkedIn: "Key insights from ESTRO24 on the optimisation…
Jul 25, 2024, 21:48 |
Insight
Stephen V Liu: What is the role for SRS to brain metastases up front for EGFR or ALK NSCLC?
Stephen V Liu shared a paper by Luke R.G. Pike et al. on X, adding: “What…
Jul 25, 2024, 14:28 |
Blog
Stephen V Liu: Alexander Drilon joins DCLung24 to discuss RET fusions in NSCLC
Stephen V Liu shared on X: "Dr. Alexander Drilon joins DCLung24 to discuss RET fusions as…
Jul 25, 2024, 14:02 |
Insight
Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?
Erman Akkus, Medical Oncologist at Ankara University, shared a paper by Luke R.G. Pike et al. on…
Jul 25, 2024, 06:32 |
Insight
Stephen Liu: Novel epigenomic cfDNA approach in diagnosis of EGFR mutant NSCLC
Stephen Liu shared a post on X about a recent paper by Jacob E. Berchuck…
Jul 25, 2024, 00:44 |
Blog
First-line management of ALK-positive NSCLC with CNS metastases - Florez Lab
Florez Lab shared on X: "Dr. Narjust Florez joins Drs. Todd Bauer and Sai-Hong Ou…
Jul 25, 2024, 00:32 |
Blog
Jarushka Naidoo: Can intratumor eschericia improve OS from ICIs in NSCLC
Jarushka Naidoo shared a post on X: ''Can intratumor eschericia (E) bring immune cells to…
Jul 24, 2024, 13:40 |
Blog
Collin Blakely: Neoadjuvant Osimertinib for the Treatment of Non–Small Cell Lung Cancer
Collin Blakely, Associate Professor of Thoracic Medical Oncology and Clinical Scientist at UCSF, shared a…
Jul 22, 2024, 12:55 |
Insight
Fascinating paper by brilliant statistician Brian Hobbs
David Hong, Medical Oncologist at MD Anderson Cancer Center, shared a post on X about a…
Jul 20, 2024, 21:29 |
Insight
Harry Sokol: The role of Faecali bacterium prausnitzii to boost ICI efficacy in cancer
Sumanta K. Pal shared a post by Harry Sokol, Professor of Gastroenterology at Greater Paris…
Jul 20, 2024, 17:09 |
Opinion
Stephen V Liu: Tina Cascone on Neoadjuvant and Perioperative Immunotherapy For Early Stage NSCLE At DCLung24
Stephen V Liu shared a post on X: "Dr. Tina Cascone from MD Anderson News…
Jul 20, 2024, 16:06 |
Blog
Ernest Nadal: Podcast on the management of CNS metastases in driver-negative NSCLC
Ernest Nadal, head of the IDIBELL research group, posted on X: "It was a pleasure…
Jul 19, 2024, 09:30 |
Blog
The latest lung cancer research at ESTRO 24
ESTRO shared on X: . "Discover the latest lung cancer research at ESTRO 24: highlights…
Jul 18, 2024, 10:41 |
Insight
Stephen Liu: Can we predict risk of immune related toxicity with immunotherapy for NSCLC
Stephen Liu shared a post on X about a recent paper by Fei Xing et…
Jul 18, 2024, 09:52 |
Insight
Raffaele Colombo: Trastuzumab rezetecan in patients with HER2-mutant NSCLC
Raffaele Colombo shared a post on X about a recent paper by Shun Lu et…
Jul 16, 2024, 03:13 |
Blog
Haniel Araujo: Efficacy of the novel RAS(ON) in KRASG12C mutant NSCLC
Haniel Araujo, Thoracic and Head and Neck Medical Oncology Fellow at MD Anderson Cancer Center, shared…
Jul 14, 2024, 06:26 |
Insight
Daniele Marinelli: NRF2-driven transcription in NSCLC
Daniele Marinelli, PhD student at the Sapienza University of Rome, shared a post on X…
Jul 12, 2024, 23:29 |
Insight
Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC
Biagio Ricciuti shared on X: "Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC…
Jul 12, 2024, 14:18 |
Blog
Updated review on targeting KRAS in NSCLC
Stephen V Liu shared on X: "Updated review on targeting KRAS in NSCLC available in…
Jul 11, 2024, 13:51 |
Blog
Christian Rolfo: Important meeting on Drug Tolerance and Resistance in NSCLC
Christian Rolfo, Associate Director of Clinical Research Center of Thoracic Oncology at The Tisch Cancer…
Jul 11, 2024, 04:40 |
Blog
Amanda Nerstad: This is hope
Amanda Nerstad, Lung cancer survivor and advocate, shared on X: "This is hope. Patient #2…
Jul 10, 2024, 16:42 |
Blog
Yakup Ergün: The effects of 960 mg sotorasib
Tejas Patil, Thoracic oncologist CU Cancer Center, shared a post by Yakup Ergün, Medical Oncologist at Antalya…
Jul 10, 2024, 11:53 |
Blog
Stephen V. Liu: Pittsburgh Annual Oncology Symposium Experts and Evidence 2024
Stephen V. Liu shared on X: “Join me for an update on Targeted Therapy in…
Jul 10, 2024, 02:17 |
Blog
Biagio Ricciuti: Resistance mechanisms in insertion-mutant NSCLC
Biagio Ricciuti shared on X: "Resistance mechanisms to EGFR TKIs in EGFR ex 20 insertion-mutant NSCLC:…
Jul 6, 2024, 12:06 |
Blog
Real world data on QTc prolongation with osimertinib
Stephen V Liu shared on X: "Real world data on QTc prolongation with osimertinib. 970 pts…
Jul 6, 2024, 11:24 |
Blog
Insights from ESTRO24 on reirradiation in NSCLC by Jonas Willmann
European Society for Radiotherapy and Oncology shared on X: "Insights from ESTRO24 on reirradiation in NSCLC…
Jul 5, 2024, 06:05 |
Insight
Baseline cardiac features and the associated risk of radiation induced cardiotoxicity
Gerry Hanna, Marie Curie Chair of Clinical Oncology at Trinity College Dublin, shared on LinkedIn:…
Jul 4, 2024, 03:53 |
Blog
Sarah Waliany: Reviewing the TRUST-1 trial investigating taletrectinib
Sarah Waliany, Thoracic Oncology Fellow at Mass General Cancer Center, shared the following post by…
Jul 3, 2024, 23:31 |
Blog
A few papers to read about Precision oncology and use of AI suggested by Vivek Subbiah
We are presenting articles suggested by Vivek Subbiah: "1. In advanced prostate cancer, deep learning…
Jul 3, 2024, 18:13 |
Blog
Alessandro Di Federico: Intrapatient variation in PD-L1 and TMB
Alessandro Di Federico, Medical Oncologist and PhD student at University of Bologna, shared a post on…
Jul 3, 2024, 17:29 |
Blog
Benjamin Besse: Stop pembro after 2 years?
Benjamin Besse, Head of Clinical Research at Gustave Roussy, shared on X: "Stop pembro after…
Jul 3, 2024, 01:51 |
Blog
Oncology Brothers: Stephen V Liu covering NSCLC where treatment is with curative intent
Oncology Brothers shared on X: "Stephen V Liu from Georgetown Lombardi covering NSCLC where treatment is…
Jul 2, 2024, 14:33 |
Blog
Mara Antonoff: Boris Sepesi presented on multidisciplinary management in early-stage NSCLC at WTSA2024
Mara Antonoff, Associate Professor Thoracic and Cardiovascular Surgery at MD Anderson Cancer Center, shared on X:…
Jul 2, 2024, 04:16 |
Insight
Olivier Calvayrac: TT-derived drug-tolerant (DT) lung cancer cells are vulnerable to FTIs
Olivier Calvayrac, Research Scientist at the Toulouse Cancer Research Center, shared a post on X…
Jul 1, 2024, 15:01 |
Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jul 1, 2024, 14:03 |
Drugs
Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients - Sarah Cannon Research Institute
Sarah Cannon Research Institute shared on LinkedIn: "Significant advancements in NSCLC treatment! SCRI's Dr. Robert Jotte…
Jul 1, 2024, 10:01 |
Blog
Stephen Chun: Long-term outcomes of IMRT for locally-advanced lung cancer
Stephen Chun made the following post on X: “Happy to report long-term outcomes of intensity modulated…
Jul 1, 2024, 03:08 |
Blog
Stephen V Liu: Phase III Adjuvant BR.31 study does not meet primary endpoint
Stephen V Liu shared on X: “Phase III ADJUVANT BR.31 study does not meet primary…
Jul 1, 2024, 02:31 |
Blog
Biagio Ricciuti receives a 2024 IASLC YIA to develop new therapies for KRAS amplified NSCLC
Biagio Ricciuti shared a post by Dana-Farber News, on X: "Thrilled to receive a 2024…
Jun 29, 2024, 15:03 |
Insight
IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable
Thomas Wu, Research physician at Genentech, shared a post by X: "Our paper just out…
Jun 29, 2024, 14:51 |
Blog
Alessio Cortellini: Immune-suppressive role of RANKL in patients with NSCLC treated with ICI
Alessio Cortellini, Assistant Professor at Campus Bio-Medico University of Rome, shared a post by Journal for…
Jun 29, 2024, 14:04 |
Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
Jun 29, 2024, 08:58 |
Insight
Nathan Pennell: EGFR mutation testing, treatment and survival in stage I–III NSCLC
Nathan Pennell, Professor and Vice Chair of Clinical Research at Cleveland Clinic, shared on X: …
Jun 28, 2024, 14:52 |
Insight
Iván R. González: ICIs in early-stage NSCLC showing promising results
Iván R. González, Medical Oncologist at Comprehensive Oncology Center, Hospital Ángeles Puebla, shared a post…
Jun 28, 2024, 11:08 |
Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 27, 2024, 13:27 |
Blog
Douglas Flora: MRD AI tests are proving to be invaluable tools in our decision-making process
Douglas Flora shared a post on LinkedIn: “As I’ve been working my way through the latest…
Jun 27, 2024, 12:11 |
Insight
Patrick Forde: What is an acceptable rate of crossover?
Patrick Forde, Co-Director of the Division of Upper Aerodigestive Malignancies Sidney Kimmel Comprehensive Cancer Center at…
Jun 27, 2024, 08:26 |
Societies
Jia Liu: Great summary of biliary tract cancer and gene target therapy at ESMOGI24
Jia Liu, Translational Researcher at The Kinghorn Cancer Centre, shared on X: "Great summary of…
Jun 26, 2024, 14:43 |
Blog
Jonathan Spicer: Incredible pace of development for patients with resectable NSCLC
Jonathan Spicer, Medical Director of the McGill Thoracic Oncology Program, shared a post on X:…
Jun 26, 2024, 12:05 |
Insight
Piotr Wysocki: Osimertinib after radiochemotherapy improves PFS in EGFR-mutated NSCLC patients – but is it really what they need?
Piotr Wysocki recently posted on LinkedIn: "The results of the LAURA study were presented during a…
Jun 26, 2024, 08:30 |
Insight
IMFINZI (durvalumab) showed improved EFS and OS for MIBC in NIAGARA Phase III trial
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results…
Jun 26, 2024, 06:12 |
Insight
Consensus Recommendations from IASLC on neoadjuvant and adjuvant treatment for NSCLC
Rami Manochakian shared a post on X: “Hot off the press! Just published in JTO and…
Jun 26, 2024, 05:25 |
Blog
Aditya Juloori: Greys Anatomy highlights COSINR trial at UChicago Cancer Center
Drew Moghanaki shared a post by Aditya Juloori, radiation oncologist at UChicago Medicine on X: “Wait. What?…
Jun 26, 2024, 04:38 |
Insight
Andy Minn: Summary of our paper on combining JAK inhibitors with anti-PD1 for lung cancer
Andy Minn, Professor at University of Pennsylvania School of Medicine, shared a post on X: "Summary…
Jun 24, 2024, 15:49 |
Insight
Tanja Obradovic: The landscape of targeting KRAS mutations just got busier
Tanja Obradovic shared on LinkedIn: . "The landscape of KRAS mutations…
Jun 24, 2024, 12:01 |
Insight
Jean-Charles Soria: Two provocative manuscripts suggest the therapeutic potential of JAK inhibition with immunotherapy in cancer
Jean-Charles Soria shared a post on LinkedIn: "Two provocative manuscripts suggest the therapeutic potential of…
Jun 23, 2024, 10:44 |
Blog
IV vs Subcutaneous amivantamab in EGFR NSCLC
Eric K. Singhi shared a post by Stephen V Liu, on X: "Absolutely agree with this! Compared with…
Jun 23, 2024, 03:25 |
Insight
Enriqueta Felip on the best way to target BRAF V600E and MET in NSCLC
Stephen Liu shared on X: "Dr. Enriqueta Felip at CIOT24 discussing the best way to…
Jun 22, 2024, 03:29 |
Insight
Triparna Sen: Celebrating 20 years of EGFR
Triparna Sen, Associate Professor at Icahn School of Medicine at Mount Sinai, posted on X: “Had…
Jun 21, 2024, 13:43 |
Insight
Luca Dezzani: We are requesting approval from the U.S. FDA EGFR-mutated NSCLC therapy
Luca Dezzani, Vice President of US Oncology Medical Affairs at Johnson & Johnson, shared a…
Jun 21, 2024, 12:59 |
Dialogues
ASCO24 Updates: Can We Treat Locally Advanced Lung Cancer Without Radiotherapy?
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Jun 21, 2024, 04:15 |
Insight
Biagio Ricciuti: Fusion partners and chromosomal breakpoints of oncogenic fusions are not stochastic
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jun 20, 2024, 01:37 |
Insight
Torrie Fields: Let’s make supportive cancer care the standard of care
Torrie Fields, Founder and Chief Executive Officer at TFA Analytics, shared a post by Ramy…
Jun 19, 2024, 12:33 |
Blog
Maria Babak: How Bevacizumab is revolutionizing treatment for multiple cancers
Maria Babak shared a post by CityU iGEM on LinkedIn: "Discover how Bevacizumab, a powerful cancer…
Jun 18, 2024, 09:36 |
Blog
Drew Moghanaki: Dr. Wen-Zhao Zhong reminding us of the fanfare around drugs and surgery for NSCLC
Drew Moghanaki shared on X: "Dr. Wen-Zhao Zhong presents a slide at ELIXR24 reminding us…
Jun 16, 2024, 17:20 |
Insight
Yvonne Diaz: EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer
Yvonne Diaz, Co-founder of Oncogene Cancer Research, shared a post on X: “Great to see that…
Jun 16, 2024, 15:16 |
Insight
Cost of care discussions in medical records of patient with advanced NSCLC and melanoma - ACS Journal Cancer
Robin Yabroff, Scientific Vice President at the American Cancer Society, recently shared a post by…
Jun 16, 2024, 13:37 |
Drugs
Stephen Liu: FDA approves repotrectinib for NTRK fusion positive solid tumors
Stephen Liu recently shared a post on X: “FDA approves repotrectinib for NTRK fusion positive…
Jun 16, 2024, 12:44 |
Insight
Mara Antonoff: Dr Heather Wakelee clarifies the role of chemotherapy in NSCLC
Mara Antonoff, Associate Professor of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, shared on…
Jun 15, 2024, 05:25 |
Blog
Leora Horn: An update on our recent review published in Trends in Cancer
Leora Horn, Head of Clinical Development, Late Oncology at AstraZeneca, shared a post on LinkedIn: "Together…
Jun 14, 2024, 20:04 |
Blog
Drew Moghanaki: Jonathan Spicer has us debating the treatment for stage III NSCLC
Drew Moghanaki shared a post on X: "Just like that, the clairvoyant Jonathan Spicer now has…
Jun 14, 2024, 05:42 |
Blog
EGFR Resisters and Young Lung Cancer Initiative are hosting a webinar
Young Lung Cancer Initiative shared on X: "Live Event Alert! EGFR Resisters and Young Lung…
Jun 13, 2024, 15:48 |
Insight
Stephen Liu on a paper by Natasha Leighl, et al.
Stephen Liu recently shared a post on X: "PALOMA-3 results at Journal of Clinical Oncology…
Jun 13, 2024, 13:34 |
Insight
Stephen Liu: Report on brain metastases in patients with KRAS NSCLC
Stephen Liu shared on X/Twitter: "Report on brain metastases in patients with KRAS NSCLC in phase…
Jun 12, 2024, 07:44 |
Career
Sucheta Guinan: I’m starting a new position as Sr. Director, US HCP Marketing, Oncology at Regeneron!
Sucheta Guinan, Senior Director US HCP Marketing Lead, Oncology at Regeneron, shared on LinkedIn: “I’m…
Jun 11, 2024, 12:52 |
Dialogues
ASCO24 Updates: Survival Outcomes: Neoadjuvant vs. Adjuvant Therapy in NSCLC
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Jun 10, 2024, 16:18 |
Blog
Estela Rodriguez: Disparities in survival among patients with metastatic NSCLC via JNCI
Estela Rodriguez shared a post on X: "Racial and socioeconomic disparities in survival among patients with…
Jun 10, 2024, 00:53 |
Insight
Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC
Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on…
Jun 7, 2024, 10:53 |
Blog
Drew Moghanaki: All patients getting CRT for locally advanced NSCLC must undergo EGFR testing
Drew Moghanaki shared on X/Twitter: ''This presentation by Suresh S. Ramalingam marks a historical moment…
Jun 6, 2024, 04:19 |
Opinion
Roy Herbst shared the updated results from the COAST clinical trial - Yale Cancer Center
Yale Cancer Center shared a post on X: "Roy Herbst shared the updated results from…
Jun 6, 2024, 00:54 |
Blog
Discussing the practice changing LAURA trial - Two Onc Docs
Two Onc Docs shared a post on X/Twitter: ''Discussing the practice changing LAURA trial for…
Jun 4, 2024, 14:59 |
Societies
15 Posts From ASCO24 Day 4 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
Jun 4, 2024, 14:07 |
Insight
Telehealth is effective for delivering early palliative care in NSCLC patients - ASCO
American Society of Clinical Oncology (ASCO) recently shared on LinkedIn: "ASCO24 study shows telehealth is…
Jun 4, 2024, 12:54 |
Blog
Suresh Ramalingam was met with a standing ovation at ASCO24 - Conquer Cancer, the ASCO Foundation
Conquer Cancer, the ASCO Foundation shared on LinkedIn: "We are excited and proud to share that…
Jun 4, 2024, 09:39 |
Societies
ASCO24 Day 4 Highlights by The Oncology Brothers
The Oncology Brothers shared on X: "ASCO24 Day 4 Highlights: 1. ICTAN: Adjuvant anti-EGFR duration…
Jun 3, 2024, 22:53 |
Insight
Paul Healy: AstraZeneca and Daiichi Sankyo have announced positive results from datopotamab deruxtecan in certain lung cancer patients
Paul Healy, Director of PHARMeMED, shared on LinkedIn: "AstraZeneca (AZ) and Daiichi Sankyo have announced positive…
Jun 3, 2024, 12:44 |
Insight
Yakup Ergün: Adding LCT does not improve survival in oligometastatic NSCLC
Yakup Ergün, Medical Oncologist at Antalya City Hospital, recently shared a post on X: "NRG-LU002:…
Jun 3, 2024, 11:57 |
Societies
Tanja Obradovic: Very dynamic day at ASCO2024
Tanja Obradovic shared a post on LinkedIn: "Very dynamic ASCO2024 day as we learned quite…
Jun 2, 2024, 22:20 |
Insight
Sylvester Cancer study on immunotherapy drug durvalumab shows limited access globally due to cost constraints
Access to Targeted Lung Cancer Drug Is Cost-Prohibitive Globally Many countries with national healthcare systems…
Jun 2, 2024, 11:16 |
Insight
Giannis Mountzios: Lorlatinib in ALK positive NSCLC sets a new benchmark in Precision Oncology
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jun 2, 2024, 10:50 |
Societies
Jordi Remon: Comparison of treatments in EGFRm NSCLC at ASCO24
Jordi Remon, a Thoracic oncologist at CIOCC Barcelona, recently posted on X: "For patients with…
Jun 1, 2024, 22:56 |
Insight
Aakash Desai: All set to showcase exciting NSCLC and lung cancer research at ASCO Lung24
Aakash Desai, Assistant Professor at O'Neal Comprehensive Cancer Center at UAB, shared on LinkedIn: …
Jun 1, 2024, 21:13 |
Blog
Bartomeu Massuti on Optó-TROP 01 Lung study at ASCO24
Bartomeu Massuti, Associate Professor at Miguel Hernandez University of Elche, shared a post on X: "Optó-TROP…
Jun 1, 2024, 21:10 |
Blog
LUNGevity Foundation - Subcutan injection or IV infusion for EGFR + NSCLC
LUNGevity Foundation shared a post on X: "Subcutan injection or IV infusion? Does it matter? Phas…
Jun 1, 2024, 14:46 |
Societies
15 Posts From ASCO24 Day 1 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
Jun 1, 2024, 14:36 |
Blog
Albert Bourla: Results from our Phase 3 clinical trial evaluating treatments for patients with advanced ALK-positive NSCLC shared at ASCO24
Albert Bourla, Chairman and Chief Executive Officer of Pfizer, shared a post on LinkedIn: "We’re making…
Jun 1, 2024, 12:35 |
Insight
Duaa Kanan: Check out our abstract on the role of CPS for PD-L1 expression in patients with NSCLC
Duaa Kanan, Internal Medicine Resident Physician at the University of Illinois College of Medicine Peoria,…
1
2
3
All:
250
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube